MYRIAD GENETICS, INC.
-
Open
12.67
-
Previous Close
13.11
-
Volume (Avg)
29.43k (1.22M)
-
Day's Range
12.67-13.01
-
52Wk Range
9.24-48.40
-
Market Cap.
1.07B
-
Dividend Rate ( Yield)
-
-
Beta
1.44
-
Shares Outstanding
74.55M
-
P/E Ratio (EPS)
581.41 (-)
Top Stories
-
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
Business Insider 3 days agoMyriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis ® Diagnostic System (i.
-
Myriad Announces Board of Directors Leadership Transition
YAHOO! -
Myriad Genetics Inc.
Barron's -
A Look At The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Yahoo! Sports -
Myriad Genetics, Inc. Common Stock (MYGN) Institutional Holdings
Nasdaq 3/24/2020Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
-
Myriad Genetics, Inc. (MYGN), Overstock.com, Inc. (OSTK) & Waitr Holdings Inc. (WTRH) - Bronstein, Gewirtz & Grossman, LLC
Bloomberg -
MYGN.O - Myriad Genetics, Inc. Profile | Reuters
Reuters -
Global Immunotherapy Drug Market is Projected to Grow at a CAGR of 13.49 % During the Forecast Period 2020-2027
MarketWatch -
Myriad Files Application In Japan To Expand Indications For BRACAnalsyis
Nasdaq -
Companion Diagnostics Market Size Worth USD 12,647 Million | 15.4% CAGR By 2023
Medgadget -
Global Companion Diagnostics Market to 2026 - Opportunity Analysis for New Entrants - ResearchAndMarkets.com
Benzinga.com -
Genetic Testing Industry Insights, 2017-2022 - Growing Awareness, Technological Advances in Genetic Sequencing, Rising Incidences of Genetic Diseases
Digital Journal -
Companion Diagnostics Market Qualitative Analysis, Product Scope, Overview, Types, Application, Key Players
MarketWatch -
Myriad Grows Internationally, Hereditary Cancer Revenues Soft
YAHOO! -
Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer
GlobeNewswire 3 days agoMarch 30, 2020 07:05 ET | Source: Myriad Genetics, Inc. SALT LAKE CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision ...
-
Myriad Genetics, Inc.
U.S. News & World Report -
Myriad Announces Board of Directors Leadership Transition
GlobeNewswire -
Myriad Genetics Inc.
Barron's
![image beacon](https://web.vortex.data.msn.com/collect/v1/t.gif?name='Ms.Webi.PageView'&ver='2.1'&appId='JS:MSN'&ext-app-env='prod'&ext-javascript-libver='4.0.0-beta-10'&ext-user-localId='t:219229B68BBA67C8239427168A476673'&*baseType='Ms.Content.PageView'&*isJs=False&*title=''&*isLoggedIn=False&*isManual=True&*serverImpressionGuid='7a88a9d6-c119-4073-8f9c-681082815b29'&-ver='1.0'&-impressionGuid='7a88a9d6-c119-4073-8f9c-681082815b29'&-pageName='stocksummary'&-uri='http%253A%252F%252Fwww.msn.com%252Fen-us%252Fmoney%252Fstockdetails%252Ffi-a1y7jc%253FSymbol%253DMYGN'&-referrerUri=''&-pageTags='{"pg.t":"data"%2C"pg.p":"prime"%2C"pg.c":""%2C"ex":""%2C"rid":"7a88a9d6-c119-4073-8f9c-681082815b29"%2C"di":"7290"%2C"partner":"Thomson%2BReuters"%2C"publcat":"Thomson%2BReuters%252c%2BLLC"%2C"cvs":"Browser"%2C"subcvs":"finance"%2C"entityId":"a1y7jc"%2C"entitySrc":"fi"%2C"provid":"AAf3a78"%2C"dpt":"stockdetails"%2C"sdpt":""%2C"ar":"0"%2C"dgk":"downlevel.pc"%2C"imd":"0"%2C"parentId":""%2C"pgIdx":""%2C"pgTot":""%2C"anoncknm":""%2C"afd":""%2C"issso":"0"%2C"aadState":"0"}'&-behavior=0&-market='en-us'){kind=small}